Venrock Healthcare Capital Partners III, L.P. 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:06 pm Unchanged | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 4.600% | 0 (Unchanged) | Filing |
| 2024-11-14 5:50 pm Sale | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 5.300% | -1,049,066 (-28.09%) | Filing |
| 2024-02-14 8:47 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 3,734,514 9.990% | 3,734,514 (New Position) | Filing |